Kim E J, Lee M G
College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, Republic of Korea.
Biopharm Drug Dispos. 2001 May;22(4):147-56. doi: 10.1002/bdd.267.
The importance of plasma protein binding of intravenous furosemide in circulating blood for its urinary excretion and hence its diuretic effects in mutant Nagase analbuminemic rats was reported. Based on the furosemide report, the diuretic effects of another loop diuretic, bumetanide, could be expected in analbuminemic rats if plasma protein binding of bumetanide is considerable in the rats. This was proved by this study. After intravenous administration of bumetanide, 10 mg/kg, to analbuminemic rats, the plasma protein binding of bumetanide was 36.8% in the rats mainly due to considerable binding to alpha- and beta-globulins (this value, 36.8%, was considerably greater than only 12% for furosemide), and hence the percentages of intravenous dose of bumetanide excreted in 6 h urine as unchanged drug was 16.0% in the rat (this value was considerably greater than only 7% for furosemide). After intravenous administration of bumetanide to analbuminemic rats, the area under the plasma concentration-time curve from time zero to time infinity (1012 compared with 2472 microg min/mL) was significantly smaller [due to significantly faster both renal clearance (1.49 compared with 0.275 ml/min/kg) and nonrenal clearance (8.30 compared with 3.71 ml/min/kg)], terminal half-life (9.94 compared with 22.4 min) and mean residence time (4.25 compared with 5.90 min) were significantly shorter (due to faster total body clearance, 9.88 compared with 4.05 ml/min/kg), and amount of 6 h urinary excretion of unchanged bumetanide (559 compared with 261 microg, due to increase in intrinsic renal excretion) was significantly greater than that in control rats. The 6 h urine output and 6 h urinary excretions of sodium, chloride and potassium were comparable between two groups of rats although the 6 h urinary excretion of bumetanide was significantly greater in analbuminemic rats. This could be explained by the following. The amount of urinary excretion of bumetanide was significantly greater in analbuminemic rats than that in control rats only between 0 and 30 min urine collection. In both groups of rats, the urinary excretion rates of bumetanide during 0-30 min reached a upper plateau with respect to urine flow rate as well urinary excretion rates of sodium, potassium and chloride, therefore, the diuretic effects (6 h urine output and 6 h urinary excretions of sodium, potassium and chloride) were not significantly different between two groups of rats.
有报道称,静脉注射速尿在循环血液中的血浆蛋白结合对于其经尿液排泄以及在突变的长谷川无白蛋白血症大鼠中的利尿作用具有重要意义。基于速尿的报道,如果布美他尼在大鼠中的血浆蛋白结合率较高,那么可以预期另一种袢利尿剂布美他尼在无白蛋白血症大鼠中也会有类似的利尿作用。本研究证实了这一点。给无白蛋白血症大鼠静脉注射10mg/kg布美他尼后,布美他尼在大鼠中的血浆蛋白结合率为36.8%,主要是由于与α球蛋白和β球蛋白的结合较多(该值36.8%远高于速尿的仅12%),因此静脉注射剂量的布美他尼在6小时尿液中以原形药物形式排泄的百分比在大鼠中为16.0%(该值远高于速尿的仅7%)。给无白蛋白血症大鼠静脉注射布美他尼后,从时间零点到无穷大的血浆浓度-时间曲线下面积(分别为1012和2472μg·min/mL)显著更小[这是由于肾清除率(分别为1.49和0.275ml/min/kg)和非肾清除率(分别为8.30和3.71ml/min/kg)均显著更快],末端半衰期(分别为9.94和22.4分钟)和平均驻留时间(分别为4.25和5.90分钟)显著更短(这是由于总体清除率更快,分别为9.88和4.05ml/min/kg),并且布美他尼6小时尿液中原形药物的排泄量(分别为559和261μg,这是由于内在肾排泄增加)显著高于对照大鼠。两组大鼠的6小时尿量以及钠、氯和钾的6小时尿排泄量相当,尽管无白蛋白血症大鼠中布美他尼的6小时尿排泄量显著更高。这可以通过以下原因来解释。仅在收集0至30分钟尿液期间,无白蛋白血症大鼠中布美他尼的尿排泄量显著高于对照大鼠。在两组大鼠中,0至30分钟期间布美他尼的尿排泄率相对于尿流率以及钠、钾和氯的尿排泄率均达到一个较高的平台期,因此,两组大鼠的利尿作用(6小时尿量以及钠、钾和氯的6小时尿排泄量)没有显著差异。